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Context: Pretreatment with α-adrenergic receptor blockers is recommended to prevent 
hemodynamic instability during resection of a pheochromocytoma or sympathetic 
paraganglioma (PPGL).
Objective: To determine which type of α-adrenergic receptor blocker provides the best efficacy.
Design: Randomized controlled open-label trial (PRESCRIPT; ClinicalTrials.gov NCT01379898)
Setting: Multicenter study including 9 centers in The Netherlands.
Patients: 134 patients with nonmetastatic PPGL.
Intervention: Phenoxybenzamine or doxazosin starting 2 to 3 weeks before surgery using a 
blood pressure targeted titration schedule. Intraoperative hemodynamic management was 
standardized.
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Main Outcome Measures: Primary efficacy endpoint was the cumulative intraoperative time 
outside the blood pressure target range (ie, SBP >160 mmHg or MAP <60 mmHg) expressed as 
a percentage of total surgical procedure time. Secondary efficacy endpoint was the value on a 
hemodynamic instability score.
Results: Median cumulative time outside blood pressure targets was 11.1% (interquartile 
range [IQR]: 4.3–20.6] in the phenoxybenzamine group compared to 12.2% (5.3–20.2)] in the 
doxazosin group (P = .75, r = 0.03). The hemodynamic instability score was 38.0 (28.8–58.0) and 
50.0 (35.3–63.8) in the phenoxybenzamine and doxazosin group, respectively (P = .02, r = 0.20). 
The 30-day cardiovascular complication rate was 8.8% and 6.9% in the phenoxybenzamine and 
doxazosin group, respectively (P = .68). There was no mortality after 30 days.
Conclusions: The duration of blood pressure outside the target range during resection of 
a PPGL was not different after preoperative treatment with either phenoxybenzamine or 
doxazosin. Phenoxybenzamine was more effective in preventing intraoperative hemodynamic 
instability, but it could not be established whether this was associated with a better clinical 
outcome. (J Clin Endocrinol Metab 105: 1–11, 2020)
Key Words:  pheochromocytoma, sympathetic paraganglioma, α-adrenergic receptor blocker, 
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Pheochromocytoma and sympathetic paraganglioma (PPGL) are neuro-endocrine tumors originating 
from chromaffin cells in the adrenal medulla and extra-
adrenal sympathetic paraganglia, respectively (1). 
Overproduction of catecholamines is a key feature of 
PPGL and responsible for an increased cardiovascular 
risk (2–4). Curative surgical resection is the treatment of 
choice except in cases of metastatic disease (5).
Resection of a PPGL is associated with a high risk 
of hemodynamic instability and subsequent cardio-
vascular complications due to uncontrolled release of 
catecholamines in response to various anesthesiologic 
and surgical stimuli (6–8). To minimize intraoperative 
hemodynamic instability, pretreatment with an 
α-adrenergic receptor blocker is recommended to 
antagonize the α-receptor mediated vasoconstrictive 
effects of catecholamines (5,9). Two frequently pre-
scribed drugs for this purpose are phenoxybenzamine, 
a nonselective and noncompetitive α 1- and α 2-ad-
renergic receptor blocker, and doxazosin, a se-
lective and competitive α 1-adrenergic receptor 
blocker. Studies evaluating pretreatment with either 
phenoxybenzamine or doxazosin have shown con-
flicting results with respect to intraoperative blood 
pressure control. Whereas some studies suggested 
phenoxybenzamine to be superior to doxazosin, other 
investigators found the opposite or did not find any 
difference (10–14). Without exception, however, these 
studies were nonrandomized and retrospective in de-
sign and predominantly small-sized. Apart from blood 
pressure levels, hemodynamic instability is also re-
flected by the amount of vasoactive medication and 
intravenous fluids required to correct an abnormal 
blood pressure (15–17).
The present randomized multicenter study was initi-
ated to compare the efficacy of pretreatment with either 
phenoxybenzamine or doxazosin on the intraoperative 
hemodynamic stability during PPGL resection.
Materials and Methods
Pheochromocytoma Randomized Study Comparing 
Adrenoreceptor Inhibiting Agents for Preoperative Treatment 
(PRESCRIPT) trial was an investigator-initiated multicenter, 
randomized controlled, open-label trial conducted between 
January 2012 and December 2017 at 9 sites in The Netherlands. 
The trial protocol was approved by the institutional review 
board of the University Medical Center Groningen, University 
of Groningen, The Netherlands, in compliance with the 
Dutch Medical Research Involving Human Subjects Act and 
the Declaration of Helsinki. All patients provided written 
informed consent. The PRESCRIPT trial has been regis-
tered under ClinicalTrials.gov number NCT01379898. The 
Consolidated Standards of Reporting Trials statement was 
followed for presentation of the current study (18).
Participants
Adult patients aged 18 years or older with a recently diag-
nosed PPGL and an indication for surgical resection were 
considered eligible. Inclusion criteria were a diagnosis of 
nonmetastatic PPGL with elevated plasma or urinary (nor)
metanephrine concentrations, a minimum tumor diameter of 
1  cm on computed tomography or magnetic resonance im-
aging, and visualization on functional imaging (eg, I123-MIBG 
scintigraphy or [18F]DOPA-PET). Exclusion criteria were 
metastatic PPGL, severe hemodynamic instability necessitating 
presurgical admission to the intensive care unit, or pregnancy.
Randomization and procedures
Patients were randomized to pretreatment with either 
phenoxybenzamine or doxazosin extended-release in a 1:1 
ratio using randomly permuted blocks with alternating 
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block sizes of 2 and 4 stratified by center with interactive 
Web-based randomization software. Before the start of pre-
treatment, blood samples were drawn after 30 min of supine 
rest and stored at –80°C until determination of plasma free 
(nor)metanephrine and catecholamines concentrations using 
high-pressure liquid chromatography tandem mass spectrom-
etry with online solid-phase extraction in a central reference 
laboratory (19). Treatment was started 2 to 3 weeks before 
surgery using blood pressure guided dose titration with a 
maximum dosage of 70  mg phenoxybenzamine twice daily 
or 24 mg doxazosin twice daily (Fig. 1), in accordance with 
the maximum dosages previously reported for this indication 
(10). It was at the discretion of the treating physician whether 
the drug treatment would take place in the outpatient or in-
patient clinic. During the whole pretreatment period, blood 
pressure and heart rate were measured twice daily with a cer-
tified automated electronic blood pressure monitor just before 
ingestion of the study drugs. Each measurement consisted of 
a single recording after 5 min of supine rest and subsequently 
after 3 min in upright posture. Blood pressure and heart rate 
measurements were either performed at home by the pa-
tients themselves after careful instructions or at the hospital 
by medical personnel. Target values were a blood pressure 
<130/80 mmHg in the supine position and a systolic blood 
pressure between 90 and 110 mmHg in the upright position 
(20). Nifedipine extended-release 30 to 90 mg once daily was 
added when these targets were not reached despite a max-
imum dosage of either study drug. Heart rate target values 
were <80 bpm and <100 bpm in the supine and upright pos-
ition, respectively. Metoprolol extended-release 50 to 200 mg 
once daily was added in case these targets were not achieved. 
In addition, patients were advised to consume a diet con-
taining at least 15 g of sodium chloride per day (5). During 
the last 24 hours before surgery, 2 liters of 0.9% saline was 
administered intravenously. Resection of the PPGL was post-
poned if the supine blood pressure was >160/100 mmHg on 
the day before surgery. In each participating center, patients 
were treated by a dedicated team of endocrinologists, sur-
geons, and anesthesiologists.
Blood pressure and heart rate during surgery were moni-
tored by continuous intra-arterial measurement. Hemodynamic 
management was performed using a standardized operating 
procedure describing in detail the anesthesiologic procedures 
including the indications for pharmacological interventions and 
the preferred vasoactive medication. All supplementary material 
and figures are located in a digital research materials repository 
(21). Intraoperative hemodynamic targets were systolic blood 
pressure <160 mmHg, mean arterial pressure >60 mmHg, and 
heart rate <100 bpm. Administration of vasoactive medica-
tion was only allowed when hemodynamic variables were out-
side these targets. After surgery, patients were monitored at the 
postanesthesia or intensive care unit. Postoperative pharmaco-
logical interventions to correct hemodynamic deviations were 
applied according to the standard operating procedure. We ex-
tracted all data on blood pressure, heart rate, intravenous volume 
therapy, and vasoactive medication from the electronic patient 
data monitoring system starting at induction of anesthesia and 
ending at discharge from the postanesthesia care unit or intensive 
care unit. Both duration and amplitude of hemodynamic vari-
ables outside the target range were assessed and cumulative dos-
ages of vasoactive medication were calculated.
Outcome measures
The primary endpoint of our study was the cumulative 
intraoperative time outside the blood pressure target range, 
expressed as a percentage of the time interval between induc-
tion of anesthesia (ie, first administration of propofol) and 
suturing of the incision. As a secondary efficacy endpoint, 
we used the Hemodynamic Instability score (HI-score), a val-
idated semiquantitative score reflecting the degree of hemo-
dynamic instability (17). In short, the HI-score consists of 3 
intraoperative components: hemodynamic variables (ie, blood 
pressure and heart rate), cumulative dosage of vasoactive 
medication, and fluid therapy. For each of these 3 components, 
incremental points are attributed according to the magnitude 
of deviation from predefined thresholds as well as infusion 
rates of vasoactive drugs and fluids. Thus, a higher HI-score 
Figure 1. Flow-chart of the trial procedure.
Abbreviations: BP, blood pressure; HR, heart rate; ER, extended-release; i.v., intravenous.
Copyedited by: OUP
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/105/7/dgz188/5622983 by Erasm
us U
niversiteit R
otterdam
 user on 10 June 2020
4  Buitenwerf et al  α-Adrenergic Blockers before Pheochromocytoma Surgery J Clin Endocrinol Metab, July 2020, 105(7):1–11
represents a higher degree of overall hemodynamic instability. 
For the present study, we modified the original HI-score by 
including the dosages of vasodilating drugs and β-adrenergic 
receptor blockers (21).
Other secondary efficacy endpoints were (i) the frequency, dur-
ation, and magnitude of a systolic blood pressure >160 mmHg; 
mean arterial pressure <60 mmHg; and heart rate >100 bpm; (ii) 
number and cumulative dosages of intraoperatively administered 
vasoactive drugs; and (iii) duration of postoperative administra-
tion of vasopressive drugs. Safety endpoints were cardiovascular 
complications and mortality from the first administration of 
study medication until 30 days after surgery. In addition, the fre-
quency of postoperative glucose levels ≤3.5 mmol/L and length 
of hospital stay were assessed. Preoperative adverse events were 
assessed and graded according to the Common Terminology 
Criteria for Adverse Events (22).
Statistical analysis
The sample size was calculated at a total of 134 subjects 
to demonstrate a relative reduction of 20% in intraoperative 
time outside the predefined blood pressure targets, assuming 
a frequency of 8  ±  4%, between patients pretreated with 
phenoxybenzamine or doxazosin with a power of at least 
80% and a 2-sided alpha of .05. Patients who never received 
the allocated treatment were excluded from all analyses. We 
performed all efficacy and exploratory analyses in a modi-
fied intention-to-treat population, meaning that we excluded 
subjects in whom pathological examination of the resected 
tumor was inconsistent with a PPGL since these patients 
were not at risk for catecholamine-induced hemodynamic 
instability. The safety analysis was performed in all patients 
who received the allocated treatment, including the cases in 
which another pathological diagnosis than PPGL was estab-
lished (21). Continuous variables are presented as mean ± SD 
or median (IQR) where appropriate. Categorical variables are 
presented as absolute number or percentages. Continuous vari-
ables were compared using a t test or Mann–Whitney U test. 
Nonparametrical effect sizes were calculated using Rosenthal’s 
formula (23). Categorical data were analyzed using Chi-square 
or Fisher’s exact test. Two-sided P-values <.05 were considered 
significant. All statistical analyses were carried out with SPSS 
version 23 (IBM Corporation, Armonk, NY, US).
Exploratory analyses
Exploratory analyses were carried out to assess the relation-
ship between efficacy endpoints and cardiovascular complica-
tions. In addition, determinants of hemodynamic instability 
were explored for identification of potential risk factors. The 
relationship between achievement of preoperative blood pres-
sure targets and intraoperative hemodynamic instability was 
assessed in a multivariable regression model. Further details 
are provided in the supplemental material (21).
Results
Participants
A total of 144 patients were enrolled in the trial. 
Four patients were excluded from all analyses because 
the allocated treatment was never initiated, leaving 
140 patients who completed the study. Notably, in 
6 patients the final pathology report did not reveal a 
PPGL (21). Thus, a total of 134 patients met the cri-
teria for the modified intention-to-treat population 
(phenoxybenzamine group: n  =  66, doxazosin group: 
n  =  68). The safety analysis was performed using the 
data of all 140 patients who completed the study (21).
Baseline characteristics and preoperative blood pres-
sure values are presented in Table  1. There were no 
differences between the 2 groups with respect to demo-
graphic characteristics, cardiovascular risk factors, 
American Society of Anesthesiologists physical score, 
plasma free (nor)metanephrine, or catecholamine secre-
tion patterns. The median duration of pretreatment was 
14 days in both groups, and patients received a median 
dosage of 120 (78–140) mg phenoxybenzamine or 40 
(32–48) mg doxazosin on the day before surgery. A cal-
cium channel blocker was administered to 42.4% of 
the patients in the phenoxybenzamine group compared 
to 39.7% in the doxazosin group (P =  .86). A higher 
proportion of patients in the phenoxybenzamine group 
received metoprolol (89.4% vs. 66.2%, P < .01), which 
was also prescribed at higher dosages.
Efficacy outcomes
The primary endpoint (ie, the median cumulative 
time outside the blood pressure target range during sur-
gery) was 11.1% (4.3–20.6) in the phenoxybenzamine 
group compared to 12.2% (5.3–20.2) in the doxazosin 
group (P  =  .75, r  =  0.03; Fig.  2). The median total 
HI-score was lower in the phenoxybenzamine group 
compared to the doxazosin group (38.0 [28.8–58.0] vs. 
50.0 [35.3–63.8], P = .02, r = 0.20). Peak systolic blood 
pressure, cumulative time and frequency of systolic 
blood pressure >160 mmHg, and the amount of vaso-
dilating drugs were all lower in the phenoxybenzamine 
group (Table 2). Frequency and duration of a mean ar-
terial pressure <60 mmHg or heart rate >100 bpm were 
not different between groups (Table 2). There were no 
differences between phenoxybenzamine and doxazosin 
with respect to the occurrence of postoperative hypo-
tension defined as a mean arterial blood pressure < 
60 mmHg or the use of vasoconstrictive/inotropic drugs 
(40.0% vs. 38.8%, P > .99), the proportion of patients 
requiring vasopressors (33.3% and 32.4%, P > .99), or 
the duration of vasopressor treatment (402 [161–1185] 
vs. 490 [163–1167] min, P = .98).
Adverse events
There was no 30-day perioperative mortality in 
either treatment group. Perioperative complications 
are shown in Table  3. In each treatment group, there 
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Table 1. Patient characteristics
Characteristic
Phenoxybenzamine 
(n = 66)
Doxazosin
(n = 68) P-value
Female, n (%) 34 (51.5) 36 (52.9) >.99
Age (years), mean ± SD 54 ± 15 54 ± 15 .87
BMI (kg/m2), median (IQR) 25.6 (23.6–29.0) 25.1 (22.4–29.1) .49
Smoking   .72
 Never, n (%) 28 (42.4) 32 (47.1)  
 Previous, n (%) 18 (27.3) 19 (27.9)  
 Current, n (%) 20 (30.3) 17 (25.0)  
Prior cardiovascular event,a n (%) 17 (25.8) 11 (16.7) .29
ASA class   .39
 I, n (%) 11 (16.7) 10 (14.7)  
 II, n (%) 34 (51.5) 43 (63.2)  
 III, n (%) 20 (30.3) 15 (22.1)  
 IV, n (%) 1 (1.5) 0 (0.00)  
Germline mutation, n (%)   .75
 Yes, n (%) 17 (25.8) 17 (25.0)  
 No, n (%) 37 (56.1) 37 (54.4)  
 Not assessed, n (%) 12 (18.2) 14 (20.6)  
Tumor localization, n (%)   .27
 Unilateral pheochromocytoma, n (%) 59 (89.4) 65 (95.6)  
 Bilateral pheochromocytoma, n (%) 5 (7.6) 1 (1.5)  
 Sympathetic paraganglioma, n (%) 2 (3.0) 2 (2.9)  
Maximum tumor diameter (mm), median (IQR) 38 (28–51) 42 (29–61) .62
Biochemical profile    
 Plasma-free metanephrine (nmol/L), median (IQR) 1.37 (0.29–5.64) 1.04 (0.21–3.39) .09
 Plasma-free normetanephrine (nmol/L), median (IQR) 4.33 (1.63–10.11) 3.41 (1.52–8.44) .69
 Plasma epinephrine (nmol/L), median (IQR) 0.48 (0.23–2.13) 0.40 (0.19–1.41) .26
 Plasma norepinephrine (nmol/L), median (IQR) 4.47 (2.91–11.91) 4.87 (3.03–17.69) .29
Duration of pretreatment (days), median (IQR) 14 (13–20) 14 (13–19) .86
Medication on day before surgery    
 Daily dosage study drug (mg), median (IQR) 120 (78–140) 40 (32–48) —
 Patients receiving any CCB, median (IQR) 28 (42.4) 27 (39.7%) .86
 Daily dosage nifedipine (mg),b median (IQR) 60 (30–90) 60 (30–90) .76
 Patients receiving any β-blocker, median (IQR) 59 (89.4) 45 (66.2) <.01
 Daily dosage metoprolol (mg),c median (IQR) 100 (50–150) 50 (50–100) <.01
Hemodynamic variables at randomization    
 Supine    
  SBP (mmHg), median (IQR) 144 (124–156) 138 (122–152) .44
  DBP (mmHg), median (IQR) 82 (73–88) 80 (72–87) .38
  HR (bpm), median (IQR) 76 (66–85) 71 (63–78) .02
 Upright    
  SBP (mmHg), median (IQR) 136 (122–151) 138 (124–151) .94
  DBP (mmHg), median (IQR) 84 (78–94) 85 (77–93) .94
  HR (bpm), median (IQR) 87 (73–98) 82 (76–94) .03
Hemodynamic variables day before surgery, median (IQR)    
 Supine    
  SBP (mmHg), median (IQR) 132 (116–143) 124 (115–138) .07
  DBP (mmHg), median (IQR) 74 (67–84) 69 (63–80) .02
  HR (bpm), median (IQR) 73 (64–83) 71 (65–80) .62
 Upright    
  SBP (mmHg), median (IQR) 120 (107–133) 120 (104–130) .55
  DBP (mmHg), median (IQR) 71 (65–81) 71 (64–82) .86
  HR (bpm), median (IQR) 90 (83–106) 86 (74–98) .03
Preoperative targets achieved, n (%)   <.01
 Supine BP <130/80 + upright SBP 90–110, n (%) 16 (24.6) 13 (19.7)  
 Supine BP <130/80, n (%) 13 (20.0) 28 (42.4)  
 Upright SBP 90–110, n (%) 1 (1.5) 5 (7.6)  
 None, n (%) 35 (53.8) 20 (30.3)  
Surgical approach   .69
 Laparoscopy, n (%) 48 (72.7) 44 (64.7)  
 Laparotomy, n (%) 9 (13.6) 12 (17.6)  
 Posterior retroperitoneoscopic, n (%) 9 (13.6) 12 (17.6)  
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were 6 cardiovascular complications, occurring in 6 pa-
tients of the phenoxybenzamine group and 5 patients 
of the doxazosin group (8.8% vs 6.9%, P = 0.68). The 
number of subjects with postoperative hypoglycemia 
was not different (P  =  .19). During pretreatment, ad-
verse events were reported by 80.9% and 92.4% of the 
phenoxybenzamine and doxazosin users, respectively 
(P = .08). All adverse events were graded as mild or mod-
erate (ie, grade I or II) and are listed in the supplemental 
material (21). The total length of hospital stay was 14 
(7–19) and 14 (8–18) days in the phenoxybenzamine 
and doxazosin group, respectively (P = .90).
Exploratory analyses
The primary endpoint in patients with (n  =  11) or 
without (n  =  123) a cardiovascular complication was 
11.8% (4.9–33.0) and 11.3% (5.0–20.0), respectively 
(P  =  .26). The associated HI-scores were 59.0 (43.8–
73.0) and 42.5 (29.3–59.0), respectively (P  =  .03). In 
patients with (n = 104) or without (n = 30) preopera-
tive use of a β-adrenergic receptor blocker, the primary 
endpoint was 11.4% (5.2–21.0) and 10.8% (2.5–17.4), 
respectively (P  =  .32). In addition, the associated 
HI-scores were 43.5 (32.3–59.0) and 49.0 (23.8–59.8) 
(P = .84), respectively.
Univariate analysis demonstrated that tumor size, 
total plasma-free metanephrines, and total plasma cat-
echolamines were positively associated with the primary 
endpoint. Use of doxazosin, tumor size, total plasma-
free metanephrines, and total plasma catecholamines 
were positively associated with the HI-score (21). These 
variables were subsequently tested in the multivariable 
linear regression model with the HI-score as a de-
pendent variable. Total plasma-free metanephrines did 
not contribute significantly to the model and was re-
moved. Achievement of different blood pressure targets 
was added. The final model demonstrated that the use of 
doxazosin, tumor size, and total plasma catecholamines 
were positively associated with the HI-score (21). The 
total model accounted for only a minority of the vari-
ance in HI-score (adjusted R2  = 0.16). Achievement of 
a supine blood pressure <130/80  mmHg, irrespective 
of the upright blood pressure, was negatively associ-
ated with the HI-score. Upright systolic blood pressure 
<90  mmHg was independently associated with an in-
creased HI-score (21).
Characteristic
Phenoxybenzamine 
(n = 66)
Doxazosin
(n = 68) P-value
Type of anesthesia   .86
 Total intravenous, n (%) 40 (60.6) 43 (63.2)  
 Balanced inhalation, n (%) 26 (39.4) 25 (36.8)  
Epidural anesthesia, n (%) 7 (10.6) 9 (13.6) .79
Anesthesia duration (min),d median (IQR) 140 (112–164) 145 (110–164) .91
Surgical duration (min),e median (IQR) 95 (71–127) 99 (72–120) .76
Abbreviations: BMI, body mass index; ASA, American Society of Anesthesiologists; BP, blood pressure; CCB, calcium channel blocker; IQR, interquar-
tile range; SBP, systolic blood pressure; DBP, diastolic blood pressure.
aHistory of coronary artery disease, heart failure, stroke, peripheral artery disease, or aortic aneurysm.
bNifedipine was prescribed in 87% of patients receiving any CCB. Median (IQR) shown of only these cases. In the remaining cases, amlodipine, 
barnidipine, or verapamil was prescribed. 
cMetoprolol was prescribed in 88% of patients receiving any β-blocker. Median (IQR) shown of only these cases. In the remaining cases, propranolol, 
atenolol, or bisoprolol was prescribed.
dTime from induction of anesthesia until suturing of the incision.
eTime from incision until suturing of the incision.
Table 1. Continued
Figure 2. Cumulative distribution of the percentage of total intraoperative time with blood pressure outside the target values (ie, systolic blood 
pressure >160 mmHg and MAP <60 mmHg). The x axis represents the cumulative time outside of the respective blood pressure targets. The y axis 
represents the cumulative proportion of patients.
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Discussion
In this first randomized controlled trial in patients 
scheduled for resection of a PPGL, we demonstrated 
that the cumulative time of blood pressure values out-
side the target range during PPGL surgery was not dif-
ferent after pretreatment with either phenoxybenzamine 
or doxazosin. Phenoxybenzamine was, however, more 
effective in preventing intraoperative systolic blood 
pressure above the target range and hemodynamic 
instability.
Treatment with an α-adrenergic receptor blocker 
prior to resection of a PPGL was first introduced in 
1949 and has become part of routine clinical care since 
(24,25). All previous studies on the type of α-adrenergic 
receptor blocker were retrospective in design and suf-
fered from several biases, such as the use of historical 
controls and the lack of a well-defined perioperative 
management protocol (10–14). In addition, these studies 
applied different blood pressure targets during surgery 
and raised conflicting results (10–14).
It should be noted that comparable intraoperative 
blood pressure levels can be achieved with the 
Table 3. Perioperative complications
Number of events
 
Phenoxybenzamine 
 (n = 68)
Doxazosin 
(n = 72)
Cardiovascular events   
 Asystole 0 1
 Atrial fibrillation/ 
flutter
2 0
 Acute heart failure 3 2
 Pulmonary embolism 1 0
 Postoperative 
bleeding
0 2
 Intestinal necrosis 0 1
Infection   
 Pneumonia 4 5
 Urinary tract 2 1
 Wound 1 1
 Fever of unknown 
origin
0 1
Other   
 Excessive 
postoperative pain
1 1
 Delirium 1 0
 Intestinal perforation 0 1
 Hypoglycemiaa 8 4
aGlucose ≤3.5 mmol/L during the first 24 h postoperatively.
Table 2. Secondary efficacy endpoints
Phenoxybenzamine (n = 66)
Doxazosin  
(n = 68) P-value
Systolic blood pressure >160 mmHg    
 Frequency, n (%) 34 (51.5) 49 (72.1) .02
 Duration (%), mean (IQR) 0.6 (0.0–4.6) 3.1 (0.0–8.9) <.01
Maximum SBP (mmHg), mean (IQR) 163 (146–188) 181 (159–203) <.01
Vasodilating drugs   .02
 0, n (%) 29 (43.9) 14 (20.6)  
 1, n (%) 21 (31.8) 23 (33.8)  
 2, n (%) 10 (15.2) 22 (32.4)  
 3, n (%) 6 (9.1) 8 (11.7)  
 4, n (%) 0 (0) 1 (1.5)  
Cumulative dosage MgSO4 (g), mean (IQR) 0 (0–3) 3 (0–4) <.01
Cumulative dosage phentolamine (mg), mean (IQR) 0 (0–0.5) 0 (0–4) .16
Mean arterial pressure <60 mmHg    
 Frequency, n (%) 48 (72.7) 56 (82.4) .22
 Duration (%), mean (IQR) 5.8 (0.0–16.0) 6 (1–12) .82
Minimum MAP (mmHg), mean (IQR) 53 (44–60) 51 (46–57) .36
Vasoconstrictive/inotropic drugs   .46
 0, n (%) 17 (25.8) 13 (19.1)  
 1, n (%) 24 (36.4) 27 (39.7)  
 2, n (%) 23 (34.8) 22 (32.4)  
 3, n (%) 2 (3.0) 6 (8.8)  
Infusion rate of fluids (mL/h), mean (IQR) 632 (424–945) 636 (484–896) .81
Cumulative dosage phenylephrine (µg), mean (IQR) 0 (0–425) 0 (0–300) .98
Cumulative dosage norepinephrine (µg), mean (IQR) 55 (0–660) 139 (0–603) .52
Heart rate >100 bpm    
 Frequency, n (%) 26 (39.4) 33 (48.5) .30
 Duration (%), mean (IQR) 0.0 (0.0–2.4) 0.0 (0.0–3.2) .47
Maximum HR (bpm), mean (IQR) 97 (85–115) 100 (85–115) .90
Esmolol (mg), mean (IQR) 0 (0–0) 0 (0–0) .61
Abbreviations: HR, heart rate; IQR, interquartile range; MAP, mean arterial pressure; SBP, systolic blood pressure.
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administration of a variable amount of vasoactive 
drugs and intravenous fluids by the anesthesiologist. 
The extent of these interventions has been acknow-
ledged as a fundamental marker of hemodynamic in-
stability (15–17). Therefore, we have recently developed 
and validated a clinical score for assessment of hemo-
dynamic instability during surgery (17). Using this score 
as a secondary endpoint, we found a lesser degree of 
intraoperative hemodynamic instability after pretreat-
ment with phenoxybenzamine. In particular, patients in 
the phenoxybenzamine group demonstrated a shorter 
duration of systolic blood pressure above 160 mmHg, a 
lower peak systolic blood pressure, and a concomitant 
lower requirement of vasodilating drugs. This might 
suggest that phenoxybenzamine offers a more effective 
inhibition of the α-adrenergic receptor than doxazosin, 
which could be explained by its noncompetitive antag-
onism compared to the competitive binding provided 
by doxazosin. Pretreatment with phenoxybenzamine 
did not result in more severe or a longer duration of 
postoperative hypotension, as previously suggested 
(26). We assume that this risk was minimized by the 
concomitant use of a high-sodium diet and the intra-
venous administration of saline the day before sur-
gery (20). The higher rate of co-administration of 
β-adrenergic receptor blockers among patients allocated 
to phenoxybenzamine can be explained by the occur-
rence of reflex tachycardia as a result of inhibition of 
the presynaptic α 2-adrenergic receptor. Of note, neither 
the primary endpoint nor the hemodynamic instability 
score was affected by preoperative use of β-adrenergic 
receptor blockers.
The relevance of a more stable hemodynamic profile 
seems to be supported by the observation that pa-
tients who developed a postoperative cardiovascular 
complication had a higher hemodynamic instability 
score, despite the absence of a difference in primary 
endpoint. This observation is in agreement with other 
studies describing the adverse effects of hemodynamic 
instability on postoperative outcome (9,15,16,27–31). 
The rate of cardiovascular complications was not dif-
ferent between the treatment groups, but it should be 
noted that our study was not powered for this endpoint. 
Therefore, we were unable to demonstrate whether one 
of the study drugs resulted in a better clinical outcome. 
In view of the rarity of PPGL and the current complica-
tion rate, it would not be feasible to enroll the number of 
patients required to demonstrate a relevant difference in 
perioperative cardiovascular events (32). The absence of 
mortality in our study is in agreement with the literature 
(9,33,34). In the past decades, the perioperative mor-
tality has decreased dramatically, most likely as a result 
of improvement of the medical management with use 
of α-adrenergic receptor blockers and major technical 
advances in both anesthesiology and surgery (7,20,35).
The importance of pretreatment with α-adrenergic 
receptor blockers has been questioned by some authors 
(36–38). These retrospective studies, however, suffered 
from a relevant selection bias, as both doctors’ and pa-
tients’ preferences were likely to have influenced the 
decision whether or not to initiate preoperative treat-
ment with an α-adrenergic receptor blocker. In add-
ition, these studies were confounded by the frequent 
use of antihypertensive agents other than α-adrenergic 
receptor blockers, the absence of a standardized man-
agement protocol before and during surgery, and the 
lack of detailed information on the nature and the ex-
tent of interventions required to control intraoperative 
hemodynamics. In view of the many limitations of these 
previous studies as well as the long-standing experience 
with preoperative administration of α-adrenergic re-
ceptor blockers, the use of these drugs generally remains 
recommended (5,39). The question as to whether pre-
treatment with an α-adrenergic receptor blocker could 
safely be omitted can only be answered in a randomized 
placebo-controlled trial.
The major strengths of the current study are its ran-
domized controlled design, the use of a well-defined 
perioperative management protocol, the relatively large 
sample size of patients with a rare disease, and the com-
prehensive prospective data collection. Our study also 
has some limitations. Preoperative blood pressure tar-
gets were achieved in only a minority of the participants. 
In particular, a large majority did not reach the strict 
upright blood pressure target. It should be noted, how-
ever, that these blood pressure targets are mainly based 
on expert opinion and have never been evaluated pro-
spectively before. Of potential interest, we showed that 
a preoperative supine blood pressure <130/80 mmHg is 
associated with less hemodynamic instability while an 
upright systolic blood pressure <90 mmHg is associated 
with more hemodynamic instability, as has been sug-
gested previously (10). This finding could guide future 
recommendations concerning preoperative blood pres-
sure targets. Furthermore, we did not include a placebo 
group, and study drugs were provided in an open-label 
fashion. Incorporation of a placebo arm was, however, 
considered to be unethical in view of current guide-
lines recommending pretreatment with an α-adrenergic 
receptor blocker (5,40). We have chosen for an open-
label design because blinded administration of the study 
drugs would have required a double-dummy design 
with the ensuing risk of insufficient medication adher-
ence due to the relatively large number of placebo and 
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verum drugs that would need to be ingested by the par-
ticipants. Limited availability of phenoxybenzamine 
in several countries likely affects the choice between 
phenoxybenzamine and doxazosin.
In conclusion, the duration of blood pressure being 
outside the target range during surgical resection of 
a PPGL was not different after preoperative treat-
ment with either phenoxybenzamine or doxazosin. 
Phenoxybenzamine was more effective in preventing 
intraoperative hemodynamic instability, but it could 
not be established whether its use was associated with a 
better clinical outcome.
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